Advertisement

Cytotechnology

, 50:1 | Cite as

Introduction to animal cell culture technology—past, present and future

  • O. -W. Merten
Review

Keywords

Rabies Vero Cell Rabies Virus Mammalian Cell Culture Oral Poliovirus Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Allison DW, Aboytes KA, Fong DK, Leugers SL, Johnson TK, Loke HN, Donahue LM (2005) Development and optimization of cell culture media—genomic and proteomic approaches. BioProcess Int 3:2–7Google Scholar
  2. Beale AJ (1981) Cell substrate for killed poliovaccine production. Dev Biol Standard 47:19–23Google Scholar
  3. Bebbington CR, Renner G, Thomson S, King D, Abrams D, Yarranton GT (1992) High level expression of a recombinant antibody from myeloma cells using a glutamine synthetase gene as an amplifiable selectable marker. Bio/Technology 10:169–175CrossRefGoogle Scholar
  4. Bibila TA, Ranucci CS, Glazomitsky K, Buckland BC, Aunins JG (1994) Monoclonal antibody process development using medium concentrates. Biotechnol Prog 10:87–96CrossRefGoogle Scholar
  5. Birch JR (2005) Challenges and opportunities in the large scale production of therapeutic proteins. Presented at the 19th ESACT Meeting, Harrogate/U.K., 5th–8th June, 2005Google Scholar
  6. Birch JR, Thompson PW, Boraston R, Oliver S, Lambert K (1987) The large-scale production of monoclonal antibodies in airlift fermentors. In: Webb C, Mavituna F (eds) Plant and animal cells–process possibilities. Ellis Horwood Ltd., Chichester/U.K, pp 162–171Google Scholar
  7. Brands R, Visser J, Medema J, Palache AM, van Scharrenburg GJM (1999) InfluvacTC: A safe Madin Darby Canine Kidney (MDCK) cell culture-based influenza vaccine. Dev Biol Standard 98:93–100Google Scholar
  8. Brown ME, Renner G, Field RP, Hassell T (1992) Process development for the production of recombinant antibodies using the glutamine synthetase (GS) system. Cytotechnology 9:231–236CrossRefGoogle Scholar
  9. Capstick PB, Telling RC, Chapman WG, Stewart DL (1962) Growth of a cloned strain of hamster kidney cells in suspended cultures and their susceptibility to the virus of foot and mouth disease. Nature 195:1163–1164CrossRefGoogle Scholar
  10. Chung JY, Lim SW, Hong YJ, Hwang SO, Lee GM (2004) Effect of doxycycline-regulated calnexin and calreticulin expression on specific thrombopoietin productivity of recombinant Chinese hamster ovary cells. Biotechnol Bioeng 85:539–546CrossRefGoogle Scholar
  11. Davis R, Schooly K, Rasmussen B, Thomas J, Reddy P (2000) Effect of PDI overexpression on recombinant protein secretion in CHO cells. Biotechnol Prog 16:736–743CrossRefGoogle Scholar
  12. Deshpande RR, Wittmann C, Heinzle E (2004) Microplates with integrated oxygen sensing for medium optimization in animal cell culture. Cytotechnology 46:1–8CrossRefGoogle Scholar
  13. Dorner AJ, Wasley LC, Krane MG, Kaufman RJ (1993) Protein retention in the endoplasmic reticulum mediated by GRP78. In: Oka MS, Rupp RG (eds) Cell biology and biotechnology–novel approaches to increased cellular productivity. Springer-Verlag, New York, pp 105–113Google Scholar
  14. Elias CB, Carpentier E, Durocher Y, Bisson L, Wagner R, Kamen A (2003) Improving glucose and glutamine metabolism in human HEK 293 and Trichoplusia ni insect cells engineered to express a cytosolic pyruvate carboxylase. Biotechnol Prog 19:90–97CrossRefGoogle Scholar
  15. Enders JF, Weller TH, Robbins FC (1949) Cultivation of Lansing strain of poliomyelitis virus in culture of various human embryonic tissues. Science 109:85–87CrossRefGoogle Scholar
  16. Falkner K, Gilles ED (1998) Digital image analysis: quantitative evaluation of colored microscopic images of animal cells. In: Merten O-W, Perrin P, Griffiths BJ (eds) New developments and new applications in animal cell technology. Kluwer Academic Publishers, Dordrecht/NL, pp 317–319Google Scholar
  17. Franek F, Eckschläger T, Katinger H (2003) Enhancement of monoclonal antibody production by lysine-containing peptides. Biotechnol Prog 19:169–174CrossRefGoogle Scholar
  18. Franek F, Fussenegger M (2005) Survival factor-like activity of small peptides in hybridoma and CHO cells cultures. Biotechnol Prog 21:96–98CrossRefGoogle Scholar
  19. Franek F, Hohenwarter O, Katinger H (2000) Plant protein hydorlysates: preparation of defined peptide fractions promoting growth and production in animal cells cultures. Biotechnol Prog 16:688–692CrossRefGoogle Scholar
  20. Franek F, Katinger H (2002) Specific effects of synthetic oligopeptides on cultured animal cells. Biotechnol Prog 18:155–158CrossRefGoogle Scholar
  21. Gaertner JG, Dhurjati P (1993a) Fractional factorial study of hybridoma behavior. 1. Kinetics of growth and antibody production. Biotechnol Prog 9:298–308CrossRefGoogle Scholar
  22. Gaertner JG, Dhurjati P (1993b) Fractional factorial study of hybridoma behavior. 2. Kinetics of nutrient uptake and waste production. Biotechnol Prog 9:309–316CrossRefGoogle Scholar
  23. Ge X, Hanson M, Shen H, Kostov Y, Brorson KA, Frey DD, Moreira AR, Rao G (2006) Validation of an optical sensor-based high throuput bioreactor system for mammalian cell culture. J. Biotechnol. DOI:10.1016:j.jbiotec.2005.12.009Google Scholar
  24. Gilbert P-A, Comanita L, Barrett J, Peters A, Szabat M, McFadden G, Dekaban GA (2005) Current status for high titre poxvirus stock preparation in CEF under serum-free medium conditions: implication for vaccine development. Cytotechnology 48:79–88CrossRefGoogle Scholar
  25. Girard P, Jordan M, Tsao M, Wurm FM (2001) Small-scale bioreactor system for process development and optimisation. Biochem Eng J 7:117–119CrossRefGoogle Scholar
  26. Hayflick L, Moorhead PS (1961) The serial cultivation of human diploid cell strains. Exp Cell Res 25:585–621CrossRefGoogle Scholar
  27. Hsu TA, Betenbaugh MJ (1997) Coexpression of molecular chaperone BiP improves immunoglobulin solubility and IgG secretion from Trichoplusia ni insect cells. Biotechnol Prog 13:96–104CrossRefGoogle Scholar
  28. Irani N, Wirth M, van den Heuvel J, Wagner R (1999) Improvement of the primary metabolism of cell cultures by introducing a new cytoplasmic pyruvate carboxylase reaction. Biotechnol Bioeng 6:711–721Google Scholar
  29. Jacobs JP, Jones CM, Baille JP (1970) Characteristics of a human diploid cell designated MRC-5. Nature 227:168–170CrossRefGoogle Scholar
  30. Jeong DW, Kim TS, Cho IT, Kim IY (2004) Modification of glycolysis affects cell sensitivity to apoptosis induced by oxidative stress and mediated by mitochondria. Biochem Biophys Res Commun 313:984–991CrossRefGoogle Scholar
  31. Joeris K, Frerichs J-G, Konstantinov K, Scheper T (2002) In-situ microscopy: Online process monitoring of mammalian cell cultures. Cytotechnology 38:129–134CrossRefGoogle Scholar
  32. Kallel H, Zaïri H, Rourou S, Essafi M, Barbouche R, Dellagi K, Fathallah DM (2002) Use of Taguchi’s methods as a basis to optimize hybridoma cell line growth and antibody production in a spinner flask. Cytotechnology 39:9–14CrossRefGoogle Scholar
  33. Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Eder G, Dorner F (1999) Development of a Vero cell-derived influenza whole virus vaccine. Dev Biol Standard 98:101–110Google Scholar
  34. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497CrossRefGoogle Scholar
  35. Makoschey B, Patel JR, van Gelder PTJA (2002) Serum-free produced Bovine Herpesvirus type 1 and Bovine Parainfluenza type 3 virus vaccines are efficacious and safe. Cytotechnology 39:139–145CrossRefGoogle Scholar
  36. Merten O-W (2002) Development of serum-free media for␣cell growth and production of viruses/viral vaccines—safety issues of animal products used in serum-free media. Dev Biol 111:235–259Google Scholar
  37. Merten O-W, Hannoun C, Manuguerra J-C, Ventre F, Petres S (1996) Development of a serum-free cell culture based human influenza virus vaccine production process. In: Cohen S, Shafferman A (eds). Novel strategies in the design and production of vaccines. Plenum Press, New York, pp 141–151Google Scholar
  38. Merten O-W, Palfi GE, Stäheli J, Steiner J (1987) Invasive infrared sensor for the determination of the cell number in a continuons fermentation of hybrdiomas. Dev Biol Standard 66:357–360Google Scholar
  39. Merten O-W, Wu R, Crainic R (1997) Evaluation of the serum-free medium MDSS2 for the production of polio virus on Vero cells in bioreactors. Cytotechnology 25:35–44CrossRefGoogle Scholar
  40. Montagnon BJ, Fanget B, Nicolas AJ (1981) The large-scale cultivation of Vero cells in micro-carrier culture for virus vaccine production preliminary results for killed poliovirus vaccine. Dev Biol Standard 47:55–64Google Scholar
  41. Montagnon BJ, Fanget B, Vincent-Falquet JC (1984a) Thousand liter scale microcarrier culture of Vero cells for killed polio virus vaccine. Promising results. Dev Biol Standard 55:37–42Google Scholar
  42. Montagnon BJ, Fanget B, Vincent-Falquet JC (1984) Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier. Rev Infect Dis 6(S2):210–213Google Scholar
  43. Nicolas AJ, Patet J, Vincent-Falquet JC, Branche R, Delaiti P, Montagnon B, Peyron L, Soulebot JP (1978) Production of inactivated rabies vaccine for human use on WI38 diploid cells. Results of potency tests, stability of the vaccine in liquid and freeze-dried forms. Dev Biol Standard 40:17–24Google Scholar
  44. Pay TWF, Boge A, Menard FJRR, Radlett PJ (1985) Production of rabies vaccine by industrial scale BHK21 suspension cell culture process. Dev Biol Standard 60:171–174Google Scholar
  45. Petricciani JC (1995) The acceptability of continuous cell lines: a personal and historical perspective. In: Beuvery EC, Griffiths JB, Zeijlemaker WP (eds) Animal cell technology. Developments towards the 21st century. Kluwer Academic Publishers, Dordrecht/NL, pp 605–609Google Scholar
  46. Preininger A, Schlokat U, Mohr G, Himmelspach M, Stichler V, Kyd-Rebenburg A, Plaimauer B, Turecek PL, Schwarz H-P, Wernhart W, Fischer BE, Dorner F (1999) Strategies for recombinant furin employment in a biotechnological process; complete target protein precursor cleavage. Cytotechnology 30:1–15CrossRefGoogle Scholar
  47. Pullen K, Johnston MD, Philips AW, Ball GD, Finter WB (1984) Very large scale suspension cultures of mammalian cells. Dev Biol Standard 60: 175–177Google Scholar
  48. Puskeiler R, Kaufmann K, Weuster-Botz D (2005) Development, parallelization, and automation of a gas-inducing millilitre-scale bioreactor for high-throughput bioprocess design (HTBD). Biotechnol Bioeng 89:512–523CrossRefGoogle Scholar
  49. Radlett PJ, Pay TWF, Garland AJM (1985) The use of BHK suspension cells for the commercial production of foot and mouth disease vaccines over a twenty year period. Dev Biol Standard 60:163–170Google Scholar
  50. Reichert J, Pavlou A (2004) Monoclonal antibodies market. Nat Rev 3:383–384Google Scholar
  51. Sanders PG, Hussein A, Coggins L, Wilson R (1987) Gene amplification: the Chinese hamster glutamine synthetase gene. Dev Biol Standard 66:55–63Google Scholar
  52. Stäheli J (1987) Variable screening and optimization. Dev Biol Standard 66:143–153Google Scholar
  53. Stones PB (1977) Production and control of live oral poliovirus vaccine in WI-38 human diploid cells. Dev Biol Standard 37:251–253Google Scholar
  54. Tanner M (2002) Experiences in large scale microcarrier fermentation. Presented at the first Microcarrier Workshop on Microcarriers for Large Scale Cell Culture, organized by Amersham Pharmacia, Rome/I, 3rd–4th October, 2002Google Scholar
  55. Urabe M, Ding C, Kotin RM (2002) Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 13:1925–1943CrossRefGoogle Scholar
  56. Van Steenis G, van Wezel AL, de Groot IGM, Kruijt BC (1980) Use of captive-bred monkeys for vaccine production. Dev Biol Standard 45:99–105Google Scholar
  57. Van Wezel AL, van Steenis G, Hannik ChA, Cohen H (1978) New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines. Dev Biol Standard 41:159–168Google Scholar
  58. Weuster-Botz D, Puskeiler R, Kusterer A, Kaufmann K, John GT, Arnold M (2005) Methods and milliliter-scale device for high-throughput bioprocess design. Bioprocess Biosyst Eng Doi:10.1007/s00449-005-0011-6Google Scholar
  59. Wiktor TJ, Fernandes MV, Koprowski H (1964) Cultivation of rabies virus in human diploid cell strain WI-38. J Immunol 93:353–366Google Scholar
  60. Wiktor TJ, Sokol F, Kuwert E, Koprowski H (1969) Immunogenicity of concentrated and purified rabies vaccine of tissue culture origin. Proc Soc Exp Biol Med 131:799–805Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  1. 1.Gene Therapy ProgramA.F.M.-Genethon IIIEvry Cedex 2France

Personalised recommendations